Abstract

GARCIA, Alan; BUSTILLOS-GARCIA, Gabriela A.  and  RIVERA-ROODRIGUEZ, Leonardo. Pediatric patients' head-up-tilt-test with pharmacological challenge, it is safe?. Arch. Cardiol. Méx. [online]. 2020, vol.90, n.2, pp.163-172.  Epub Oct 23, 2020. ISSN 1665-1731.  https://doi.org/10.24875/acme.m20000111.

Syncope in pediatrics represents an important cause of visits to the emergency units. For this reason, excluding a cardiac or malignant origin is essential at the time of the initial approach to determine what is the next step in management, or if they need to be referred to a pediatric cardiologist and/or electrophysiologist. Vasovagal syncope is the most frequent cause of syncope in pediatrics, in which a detailed clinical history is enough to make the diagnosis. If no diagnosis is concluded by the history, or if it is necessary to define the hemodynamic response of the patients, the head-up-tilt-test is indicated; this will trigger syncope due to an orthostatic stress caused by the angulated table (passive phase). If a negative response remains, it can be followed by a pharmacologic challenge to trigger the hemodynamic response, which is still controversial in pediatrics. The pharmacologic challenge increases the sensitivity with a slight reduction in test specificity. Although there is not a specific drug for the challenge in pediatric patients yet, the most commonly drugs used are nitrates and isoproterenol, the latter related to a great number of adverse effects. Sublingual administration of nitrates in the challenge has been proven to be ideal, effective, and safe in this specific age group. The aim of this article is to make a literature search to demonstrate the effectiveness and safety of the pharmacologic challenge during the head-up-tilt-test in pediatrics, emphasizing a study conducted at the National Institute of Cardiology with isosorbide dinitrate.

Keywords : Head-up-tilt-test (tilt-test); Isosorbide dinitrate; Syncope.